Skip to main content
main-content

Dulaglutide

News

01-13-2021 | Dulaglutide | News

Dulaglutide reduces total CVD burden in REWIND population

Participants in the REWIND trial achieved a significant reduction in total cardiovascular disease burden with dulaglutide versus placebo, report the investigators.

01-11-2021 | Dulaglutide | News

AWARD 11 supports higher dulaglutide doses

Dulaglutide doses of 3.0 and 4.5 mg are significantly more efficacious than the standard doses, with similar safety profiles, report the AWARD 11 investigators.

12-21-2020 | Dulaglutide | News

Longer treatment persistence with dulaglutide vs other GLP-1 receptor agonists in type 2 diabetes

Dulaglutide is associated with better treatment persistence and lower rates of treatment modification versus other glucagon-like peptide‑1 receptor agonists in people with type 2 diabetes, suggests a study of Swedish health registries.

09-18-2020 | Dulaglutide | News

Add-on dulaglutide may reduce liver fat in people with type 2 diabetes, NAFLD

Results from the D-LIFT trial suggest a reduction in liver fat content when dulaglutide, a glucagon-like peptide-1 receptor agonist, is added to standard care treatment in people with concurrent type 2 diabetes and non-alcoholic fatty liver disease.

01-09-2020 | Stroke | News

REWIND supports stroke protective effect for GLP-1 receptor agonists

An exploratory analysis of stroke outcomes in the REWIND trial indicates that dulaglutide may reduce the incidence but not severity of ischemic stroke in people with type 2 diabetes.

08-19-2019 | GLP-1 agonists | Highlight | News

Meta-analysis demonstrates cardioprotective effect of GLP-1 receptor agonists

Treatment with glucagon-like peptide receptor agonists reduces the risk for major adverse cardiovascular events among people with type 2 diabetes, indicate findings from a large meta-analysis.

06-10-2019 | Dulaglutide | ADA 2019 | News

Dulaglutide cardioprotective in relatively low-risk REWIND population

The glucagon-like peptide-1 receptor agonist dulaglutide has demonstrated significant cardioprotection in the REWIND trial, despite the trial population being lower risk than usual for cardiovascular outcome trials.

06-18-2018 | Dulaglutide | News

Dulaglutide feasible alternative to insulin glargine in patients with CKD

Once-weekly dulaglutide lowers glycated hemoglobin levels to a similar degree to titrated daily insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease, study findings indicate.

02-28-2018 | Dulaglutide | Highlight | News

AWARD-10 supports GLP-1 receptor agonist–SGLT2 inhibitor combination

The AWARD-10 findings show significantly improved glycemic control in patients with type 2 diabetes who add the glucagon-like peptide-1 receptor agonist dulaglutide to any sodium-glucose cotransporter 2 inhibitor.

02-01-2018 | Semaglutide | News

SUSTAIN 7 published: Semaglutide superior to dulaglutide

Semaglutide has delivered better glycemic control and weight reduction than dulaglutide for patients with type 2 diabetes in the SUSTAIN 7 trial.

09-13-2017 | GLP-1 agonists | EASD 2017 | News

Incretins research update

One of the first original research sessions of EASD 2017 included updates from the TECOS, SUSTAIN 6, and DURATION-7 and -8 trials.

Image Credits